CLSD
Income statement / Annual
Last year (2024), Clearside Biomedical, Inc.'s total revenue was $1.66 M,
a decrease of 79.77% from the previous year.
In 2024, Clearside Biomedical, Inc.'s net income was -$34.35 M.
See Clearside Biomedical, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.66 M |
$8.23 M |
$1.33 M |
$29.58 M |
$7.89 M |
$2.17 M |
$30.00 K |
$345.00 K |
$520.00 K |
$0.00 |
| Cost of Revenue |
$149.00 K
|
$355.00 K
|
$204.00 K
|
$178.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33.00 K
|
| Gross Profit |
$1.52 M
|
$7.87 M
|
$1.12 M
|
$29.40 M
|
$7.89 M
|
$2.17 M
|
$30.00 K
|
$345.00 K
|
$520.00 K
|
-$33.00 K
|
| Gross Profit Ratio |
0.91
|
0.96
|
0.85
|
0.99
|
1
|
1
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$18.59 M
|
$20.85 M
|
$19.63 M
|
$18.54 M
|
$15.07 M
|
$15.66 M
|
$68.29 M
|
$49.05 M
|
$19.46 M
|
$10.76 M
|
| General & Administrative Expenses |
$11.81 M
|
$11.87 M
|
$11.77 M
|
$11.67 M
|
$10.76 M
|
$16.82 M
|
$14.68 M
|
$9.70 M
|
$6.26 M
|
$6.56 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.81 M
|
$11.87 M
|
$11.77 M
|
$11.67 M
|
$10.76 M
|
$16.82 M
|
$14.68 M
|
$9.70 M
|
$6.26 M
|
$6.56 M
|
| Other Expenses |
$0.00
|
$0.00
|
$669.00 K
|
$1.00 M
|
-$275.00 K
|
-$466.00 K
|
$127.00 K
|
-$567.00 K
|
-$684.00 K
|
$0.00
|
| Operating Expenses |
$30.40 M
|
$32.72 M
|
$31.40 M
|
$30.20 M
|
$25.83 M
|
$32.48 M
|
$82.98 M
|
$58.75 M
|
$25.72 M
|
$17.32 M
|
| Cost And Expenses |
$30.55 M
|
$33.07 M
|
$31.60 M
|
$30.20 M
|
$25.83 M
|
$32.48 M
|
$82.98 M
|
$58.75 M
|
$25.72 M
|
$17.32 M
|
| Interest Income |
$1.46 M
|
$1.72 M
|
$669.00 K
|
$0.00
|
$335.00 K
|
$1.03 M
|
$0.00
|
$0.00
|
$0.00
|
$8.00 K
|
| Interest Expense |
$9.78 M
|
$9.36 M
|
$3.34 M
|
$0.00
|
$335.00 K
|
$1.03 M
|
$0.00
|
$0.00
|
$0.00
|
$330.00 K
|
| Depreciation & Amortization |
$226.00 K
|
$67.00 K
|
$145.00 K
|
$178.00 K
|
$180.00 K
|
$211.00 K
|
$189.00 K
|
$182.00 K
|
$65.00 K
|
$60.00 K
|
| EBITDA |
-$24.35 M |
-$23.06 M |
-$29.46 M |
-$449.00 K |
-$17.94 M |
-$30.09 M |
-$82.76 M |
-$58.23 M |
-$25.13 M |
-$17.26 M |
| EBITDA Ratio |
-14.63
|
-2.8
|
-22.2
|
-0.02
|
-2.27
|
-13.85
|
-2758.53
|
-168.77
|
-48.33
|
0
|
| Operating Income Ratio |
-17.36
|
-3.02
|
-22.82
|
-0.02
|
-2.27
|
-13.95
|
-2764.83
|
-169.3
|
-48.46
|
0
|
| Total Other Income/Expenses Net |
-$5.47 M
|
-$7.64 M
|
-$2.67 M
|
$1.00 M
|
-$275.00 K
|
-$466.00 K
|
$127.00 K
|
-$567.00 K
|
-$684.00 K
|
-$322.00 K
|
| Income Before Tax |
-$34.35 M
|
-$32.49 M
|
-$32.95 M
|
$376.00 K
|
-$18.21 M
|
-$30.77 M
|
-$82.82 M
|
-$58.98 M
|
-$25.88 M
|
-$17.64 M
|
| Income Before Tax Ratio |
-20.64
|
-3.95
|
-24.83
|
0.01
|
-2.31
|
-14.16
|
-2760.6
|
-170.94
|
-49.77
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$1.12 M
|
-$58.56 K
|
-$180.00 K
|
-$211.00 K
|
$127.00 K
|
-$182.00 K
|
-$65.00 K
|
$8.00 K
|
| Net Income |
-$34.35 M
|
-$32.49 M
|
-$34.07 M
|
$376.00 K
|
-$18.03 M
|
-$30.56 M
|
-$82.82 M
|
-$58.98 M
|
-$25.88 M
|
-$17.64 M
|
| Net Income Ratio |
-20.64
|
-3.95
|
-25.68
|
0.01
|
-2.28
|
-14.06
|
-2760.6
|
-170.94
|
-49.77
|
0
|
| EPS |
-0.47 |
-0.53 |
-0.57 |
0.0064 |
-0.39 |
-0.8 |
-2.69 |
-2.33 |
-1.97 |
-1.44 |
| EPS Diluted |
-0.47 |
-0.53 |
-0.57 |
0.0063 |
-0.39 |
-0.8 |
-2.69 |
-2.33 |
-1.97 |
-1.44 |
| Weighted Average Shares Out |
$73.80 M
|
$61.81 M
|
$60.20 M
|
$58.49 M
|
$46.51 M
|
$38.17 M
|
$30.73 M
|
$25.31 M
|
$13.11 M
|
$12.27 M
|
| Weighted Average Shares Out Diluted |
$73.80 M
|
$61.81 M
|
$60.20 M
|
$59.91 M
|
$46.51 M
|
$38.17 M
|
$30.73 M
|
$25.31 M
|
$13.11 M
|
$12.27 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
